Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has the GF Score of 84, which implies that the company
might have
Good outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents GF Score vs Drug Manufacturers Industry
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) has a GF Score of 84 as of Jul. 09, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. This is 38% above median its historical median of 61.00. Over the past decade, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' GF Score has ranged from 24.00 to 92.00.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' GF Score too high?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' current GF Score of 84 is 38% above median its 10-year median of 61.00. Over the past 10 years, this metric has ranged from a low of 24.00 to a high of 92.00. Overall, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' GF Score compare to ZTS and UTHR?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' GF Score of 84 can be compared against companies in the Drug Manufacturers industry. Historically, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' own GF Score has ranged from 24.00 to 92.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current GF Score is 84, which is 38% above median its own 10-year median of 61.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock overvalued right now?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) is currently considered Modestly Overvalued. The stock's GF Value™ is E£4.09, compared to a current price of E£4.98 — trading 21.8% above its estimated fair value. The current GF Score is 84, which is 38% above median its 10-year median of 61.00. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA), the current GF Score is 84 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock appears to be overvalued.
The current stock price of E£4.98 is trading 21.8% above its estimated GF Value™ of E£4.09.
GuruFocus considers Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents to be Modestly Overvalued.
Key valuation signals for CAI:RMDA:
GF Score: 84 (38% above median its 10-year median of 61.00)
GF Value™: E£4.09 vs. price of E£4.98 (21.8% above fair value)
No single metric tells the full story. See the CAI:RMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Business Description
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use; manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals; importing pharmaceutical reagents and raw materials necessary for serving the its purposes without trading; producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others; and producing food supplements for human use for others and by others. It has two segments: production and selling of pharmaceutical products, which generates maximum revenue; and manufacturing for others (Toll manufacturing).
84GF Score
Get the complete analysis for CAI:RMDA
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:RMDA has been successfully added to your 